Results 211 to 220 of about 102,004 (245)

Selective targeting of cortactin tandem repeat acetylation by human lysine deacetylases

The FEBS Journal, EarlyView.
Cortactin function is regulated by acetylation at several lysine residues within its tandem repeat region. Using genetic code expansion to generate cortactin variants containing precisely defined acetylation marks, we show that HDAC6 is the primary enzyme removing these modifications, with SIRT1 and SIRT2 also acting at selected sites but with lower ...
Jan Komarek, Miroslava Vosahlikova, Zsofia Kutil, Zora Novakova, Julia Kudlacova, Ruzena Tuckova, Marat Meleshin, Barbora Havlinova, Pavlina Jaklova, Jana Ptackova, Cordelia Schiene‐Fischer, Mike Schutkowski, Cyril Barinka   +12 more
wiley   +1 more source

Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase Ib Trial. [PDF]

MedComm (2020)
Rong QX, Chen MT, Yang W, Huang RQ, Shu DT, Zhang Y, Xue C, Cai YC, An X, Li HF, Shi YX.   +10 more
europepmc   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

ITF6475, a New Histone Deacetylase 6 Inhibitor, Prevents Painful Neuropathy Induced by Paclitaxel. [PDF]

Toxics
Cavaletti G, Canta A, Chiorazzi A, Pozzi E, Carozzi V, Meregalli C, Alberti P, Marmiroli P, Scuteri A, Crippa L, Fermi S, Segmani I, Vergani B, Steinkühler C, Licandro SA.   +14 more
europepmc   +1 more source

Correction: Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2/YY1 mediated downregulation of Cdh1. [PDF]

Sci Rep
Wang D, Yang Y, Cao Y, Meng M, Wang X, Zhang Z, Fu W, Duan S, Tang L.   +8 more
europepmc   +1 more source

Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. [PDF]

World J Clin Oncol
Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF.   +5 more
europepmc   +1 more source

Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells. [PDF]

Cancers (Basel)
Natarajan U, Rathinavelu A.
europepmc   +1 more source

High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma. [PDF]

Cancer Biol Ther
Danks MR, Manasterski PJ, Beetham H, Dawson JC, Elliott RJR, Culley J, Krishna R, Muir M, Thomson JP, Oswald AJ, Ewing A, Kerrison WGJ, Huang PH, Nixon I, Carragher NO, Brunton VG.   +15 more
europepmc   +1 more source

Off-target binding of the histone deacetylase inhibitor vorinostat to carbonic anhydrase II and IX. [PDF]

Acta Crystallogr F Struct Biol Commun
Gulkis MC, Hodgkinson JT, Sele CP, Knecht W, McKenna R, Fisher SZ.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Histone deacetylases

Current Opinion in Pharmacology, 2003
Post-translational modification of the histones of chromatin has a fundamental role in regulating gene expression. Enzymes involved in these epigenetic events include histone deacetylases (class I and class II), which can be inhibited by a structurally diverse group of small molecules.
Paul A, Marks, Thomas, Miller, Victoria M, Richon   +2 more
openaire   +2 more sources